menu
    • menu
    [{"orgOrder":0,"company":"OrsoBio","sponsor":"Samsara BioCapital","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrsoBio \/ Samsara BioCapital","highestDevelopmentStatusID":"5","companyTruncated":"OrsoBio \/ Samsara BioCapital"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"TLC-1235","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrsoBio \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"OrsoBio \/ Yale University"}]

    Find Dermatology Clinical Drug Pipeline Developments & Deals by OrsoBio

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OrsoBio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            OrsoBio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TLC-6740

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Samsara BioCapital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treat...

                            Details : TLC-6740 is a novel, liver-targeted mitochondrial protonophore in development for the treatment of severe lipodystrophies and other metabolic disorders. Based on active hepatic uptake and mitochondrial protonophoric activity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 02, 2022

                            Lead Product(s) : TLC-6740

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Samsara BioCapital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OrsoBio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            OrsoBio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TLC-1235

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Yale University

                            Deal Size : $2.3 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            OrsoBio Announces Exclusive License to Intellectual Property Relating to Mitochondrial Protonophores for the T...

                            Details : TLC-1235, a novel, controlled-release mitochondrial protonophore, increases energy expenditure and is expected to have broad, systemic metabolic and cardiovascular benefits, including improved insulin sensitivity, NASH, dyslipidemia, and weight loss.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 02, 2022

                            Lead Product(s) : TLC-1235

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Yale University

                            Deal Size : $2.3 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth